Globe Newswire
Andrew Murray joins as Senior Vice President to deepen Nasdaq’s Financial Technology client partnerships across Asia-Pacific as the region enters a defining era of market evolution
Bob McCooey, Vice Chairman and Head of International Listings, relocates to Singapore to broaden access to global capital for the region’s companies and investors
SINGAPORE, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the appointment of Andrew Murray as Senior... (continue reading...)
— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® —
— ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months —
— SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting —
— Establishes ORPATHYS® plus TAGRISSO® as an important targeted strategy to address... (continue reading...)
OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN alongside the Company’s Nasdaq listing with no shareholder dilution
LAKE MARY, Fla., Oct. 25, 2026 (GLOBE NEWSWIRE) -- OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a blockchain innovation company advancing real-world asset tokenization, today confirmed that its planned dual listing on Figure’s On-chain Public Equity Network... (continue reading...)
Frøya, 25 October 2026: Reference is made to the Company’s announcement of 1 October 2026 regarding the waiver agreement with its lenders. As 25 October 2026 falls on a non-banking day, the lenders have agreed to extend the waiver period until and including Monday, 26 October 2026. The Company remains in dialogue with its lenders and relevant stakeholders regarding its financing position and will provide a further update when appropriate.
For further information,... (continue reading...)
SUMPERK, Czech Republic, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Dormer Pramet has expanded its milling and threading portfolio with four product developments designed to help manufacturers increase productivity, improve process reliability and control cost per component. These additions support shoulder milling, chamfering, high-strength steel threading and high-feed roughing applications.
The launch includes the new STD11 and STD17 shoulder milling series, an expanded... (continue reading...)
More Globe Newswire
View Older Stories-
Sweet Security Research Identifies Go Implementation of Node2Shell Vulnerability, Expanding Attack Surface to Major HTTP Frameworks
-
Crypto News: Remittix Prepares Weekly Earn Payouts as Bitwise Models a Bitcoin Price Prediction of $197,000 on Global Liquidity Growth
-
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
-
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
-
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
-
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
-
Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction
-
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
-
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
-
AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations
-
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
-
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
-
Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
-
SI vs. AI: Super Intelligence Anomaly Outbreaks Trump’d by Clinton Legacy Tech (Veterans First for America)
-
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
-
KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
-
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
-
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
-
Teck Provides Update on Highland Valley Copper Operations
-
Online Cricket ID App Publishes Overview of Changing Digital Cricket Information Needs Among Indian Fans
-
UK Financial Ltd Launches MAYA CHAIN and Begins Digital Asset Migration
-
Get Cricket IDs Announces Online Information Resources for Live Cricket Updates, Match Statistics and Mobile Platform Access
-
AI-119 Vulcan Force Solution Targets California's May 2027 Frontier AI Deadline (Veterans First for America)
-
AI-119 Vulcan Force Solution Targets California's May 2027 Frontier AI Deadline (Veterans First for America)
-
Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
-
Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
-
Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
-
Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
-
2026 National Poppy Campaign launches with a donation “first” … and stunning mural: Don’t forget to Remember
-
Thousands of Ontarians to Attend ‘Together for Publicly Funded Education’ Rallies
-
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
-
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
-
DEEP Robotics Unveils Five Research Advances in Embodied AI
-
JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
-
JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
-
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
-
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
-
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
-
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
-
AirTripMaker Launches Comprehensive Business Class Flight Routes Guide from the USA to 15 Major International Destinations and Regions
-
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
-
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
-
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
-
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
-
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
-
Yangguang News Launches Global Youth Short Video Campaign “Me, Tang Poetry, and AI”
-
World Famous Liquor Brands Sustainability Index Report (2026) Released
-
Rooted in the River, Renewed with the Times: Insights from the 2026 Chishui River Forum
-
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
-
See It, Try It, Compare It: SIVP Brings CHERY’s “Technology. For Family” to Life


